Abstract
A number of neurodegenerative diseases, as Parkinson, prion, and Alzheimers diseases, has been directly associated with altered conformations of certain peptides or proteins that assemble to form highly organized aggregates, also called amyloid fibers. Glycosaminoglycans have shown to play important roles on fibrils formation, stability and resistance to proteolysis. This manuscript reviews from basic concepts on the biochemistry and biology of glycosaminoglycans to their implications in neurodegeneration with particular emphasis in pathologic protein aggregation. Prion protein, Aβ42, Tau, and α-synuclein, are all proteins that can interact with glycosaminoglycans. We document here how these interactions may modify protein conformation, aggregation kinetics, and fibers stabilization with important consequences in disease. We also raise questions which answers may make advance the understanding of the implication of GAGs in neurodegeneration.
Keywords: Glycosaminoglycans, heparan sulfate, protein aggregation, prion, Aβ42, tau, α-synuclein, neurodegeneration, amyloid fibers, synuclein, Parkinson disease, Alzheimer's disease, polypeptide aggregation, histopathological method, heparin binding proteins
Current Protein & Peptide Science
Title: Glycosaminoglycans, Protein Aggregation and Neurodegeneration
Volume: 12 Issue: 3
Author(s): Dulce Papy-Garcia, Morin Christophe, Huynh Minh Bao, Sineriz Fernando, Sissoeff Ludmilla, Sepulveda Diaz Julia Elisa and Raisman-Vozari Rita
Affiliation:
Keywords: Glycosaminoglycans, heparan sulfate, protein aggregation, prion, Aβ42, tau, α-synuclein, neurodegeneration, amyloid fibers, synuclein, Parkinson disease, Alzheimer's disease, polypeptide aggregation, histopathological method, heparin binding proteins
Abstract: A number of neurodegenerative diseases, as Parkinson, prion, and Alzheimers diseases, has been directly associated with altered conformations of certain peptides or proteins that assemble to form highly organized aggregates, also called amyloid fibers. Glycosaminoglycans have shown to play important roles on fibrils formation, stability and resistance to proteolysis. This manuscript reviews from basic concepts on the biochemistry and biology of glycosaminoglycans to their implications in neurodegeneration with particular emphasis in pathologic protein aggregation. Prion protein, Aβ42, Tau, and α-synuclein, are all proteins that can interact with glycosaminoglycans. We document here how these interactions may modify protein conformation, aggregation kinetics, and fibers stabilization with important consequences in disease. We also raise questions which answers may make advance the understanding of the implication of GAGs in neurodegeneration.
Export Options
About this article
Cite this article as:
Papy-Garcia Dulce, Christophe Morin, Minh Bao Huynh, Fernando Sineriz, Ludmilla Sissoeff, Diaz Julia Elisa Sepulveda and Rita Raisman-Vozari, Glycosaminoglycans, Protein Aggregation and Neurodegeneration, Current Protein & Peptide Science 2011; 12 (3) . https://dx.doi.org/10.2174/138920311795860188
DOI https://dx.doi.org/10.2174/138920311795860188 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Therapeutic Approaches Based on the Targeting of Microenvironment-Derived Survival Pathways in Human Cancer: Experimental Models and Translational Issues
Current Pharmaceutical Design Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies
Current Clinical Pharmacology Immune Response to Herpes Simplex Virus and γ134.5 Deleted HSV Vectors
Current Gene Therapy Regulators of the G1 Phase of the Cell Cycle and Neurogenesis
Central Nervous System Agents in Medicinal Chemistry Role of Mitochondrial Heat-shock Proteins and Immunophilins in Neuro Degenerative Diseases
Current Drug Targets Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?
Current Topics in Medicinal Chemistry Protein Amyloidogenesis Investigated by Small Angle Scattering
Current Pharmaceutical Design Rationale for the Development of Cholinesterase Inhibitors as Anti- Alzheimer Agents
Current Pharmaceutical Design PET Studies on P-Glycoprotein Function in the Blood-Brain Barrier: How it Affects Uptake and Binding of Drugs within the CNS
Current Pharmaceutical Design Apolipoprotein E-mediated Modulation of ADAM10 in Alzheimer's Disease
Current Alzheimer Research Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
Current Cancer Drug Targets Applying Epigenetics to Alzheimer’s Disease via the Latent Early–life Associated Regulation (LEARn) Model
Current Alzheimer Research The Ubiquitous Choline Transporter SLC44A1
Central Nervous System Agents in Medicinal Chemistry Plant and Animal Steroids a New Hope to Search for Antiviral Agents
Current Medicinal Chemistry Superparamagnetic Magnetite (Fe3O4) Nanoparticles for Bio-Applications
Recent Patents on Materials Science Oxidovanadium(IV) Complex Disrupts Mitochondrial Membrane Potential and Induces Apoptosis in Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Increased CRMP2 Phosphorylation is Observed in Alzheimers Disease; Does this Tell us Anything About Disease Development?
Current Alzheimer Research Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy
Current Medicinal Chemistry Autism, Mitochondria and Polybrominated Diphenyl Ether Exposure
CNS & Neurological Disorders - Drug Targets Novel Drug Delivery Systems for Releasing Growth Factors to the CNS: Focus on Alzheimer`s and Parkinson`s Diseases
Mini-Reviews in Medicinal Chemistry